Skip to main content

Table 1 Comparison between patients with or without hydroxocobalamin

From: Association between hydroxocobalamin administration and acute kidney injury after smoke inhalation: a multicenter retrospective study

CharacteristicsAll patients, N = 739Hydroxocobalamin, N = 386No hydroxocobalamin, N = 353p
At admission
 - Age in years50 (36–63)50 (38–62)48 (33–64)0.4858
 - Sex female, n (%)271 (36.7)140 (36.3)131 (37.1)0.9335
 - BMI in kg/m225 (22–28)24 (22–28)25 (22–28)0.2416
 - Prehospital cardiac arrest (%)46 (6.2)42 (10.9)4 (1.1)< 0.0001
 - Prehospital GSC /1515 (9–15)13 (5–15)15 (14–15)< 0.0001
Comorbidities
 - CKD, n (%)6 (0.8)6 (1.6)0 (0)0.0315
 - CHT, n (%)141 (19.1)71 (18.4)70 (19.9)0.6872
 - Diabetes mellitus, n (%)54 (7.3)33 (8.5)21 (6)0.2243
 - Peripheral artery disease, n (%)22 (3)9 (2.3)13 (3.7)0.3882
 - CHF, n (%)33 (4.5)20 (5.2)13 (3.7)0.4197
Burn characteristic
 - Burn, n (%)577 (78.1)286 (74.1)291 (82.4)0.0081
 - TBSA %20 (3–47)15 (0–45)24 (6–50)0.0163
 - Deep burn TBSA %9 (0–30)5 (0–30)10 (0–32)0.1985
SOFA at admission4 (1–7)5 (2–8)2 (0–5)< 0.0001
MAP in mmHg86 (72–101)86 (68–101)86 (73–101)0.4383
Vasopressors, n (%)226 (30.6)153 (39.6)73 (20.7)< 0.0001
HbCO %3.6 (1.9–9.7)7 (3–15)3 (2–5)< 0.0001
Biological data
 - Plasma lactate in mmol/L3.0 (1.8–5.2)3.5 (2.1–6)2.6 (1.4–4.1)< 0.0001
 - Serum creatinine at admission in μmol/L76 (59–101)82 (63–106)71 (56–93)0.0031
 - Maximal serum creatinine in μmol/L100 (73–162)108 (77–182)90 (71–137)0.0027
Inhalation fibroscopic status, n (%)305 (41.3)105 (27.5)200 (56.7)< 0.0001
 - Grade 0, n1 (0.1)0 (0)1 (0.3)1
 - Grade 1, n121 (16.4)31 (8)90 (25.5)< 0.0001
 - Grade 2, n110 (14.9)37 (9.6)73 (20.7)< 0.0001
 - Grade 3, n73 (9.9)37 (9.6)36 (10.2)0.8764
During ICU hospitalization
 - In-ICU mortality, n (%)243 (32.9)147 (38.1)96 (27.2)0.0022
 - AKI in the first week, n (%)288 (39)166 (43)122 (34.6)0.0229
 - Stage of AKI
  - Stage 1, n (%)102 (13.8)52 (13.5)50 (14.2)0.8682
  - Stage 2, n (%)39 (5.3)22 (5.7)17 (4.8)0.7099
  - Stage 3, n (%)147 (19.9)92 (23.8)55 (15.6)0.0066
  - Severe AKI, n (%)186 (25.2)114 (29.5)72 (20.4)0.0055
 RRT at day 7, n (%)136 (18.8)86 (22.3)50 (14.2)0.006
 - RRT in ICU, n (%)183 (24.8)107 (27.7)76 (21.5)0.0626
 - MAKE, n (%)313 (42.4)187 (48.4)126 (35.7)0.0006
 - Shock in ICU, n (%)402 (54.4)225 (58.3)176 (50)0.0261
 - Length of stay in ICU in days15 (3–44)11 (2–36)22 (3–50)0.0161
 - SAPS242 (27–60)49 (31–77)37 (23–54)< 0.0001
 - In-ICU survival, n (%)496 (67.1)239 (61.9)257 (72.8)0.0022
Nephrotoxic in ICU
 - Aminoglycoside during hospitalization188 (25.4)81 (21)107 (30.3)0.0047
 - Glycopeptide during hospitalization41 (5.5)16 (4.1)25 (7.1)0.1138
 - Contrast agent74 (10)48 (12.4)26 (7.4)0.0299
  1. All data are expressed as median ± 25–75 interquartile or percentage (%)
  2. BMI body mass index, GCS Glasgow coma scale, CKD chronic kidney disease, CHT chronic hypertension, CHF chronic heart failure, TBSA total body surface area, SOFA sequential organ failure assessment, MAP mean arterial pressure, HbCO carboxy hemoglobin, ICU intensive care unit, AKI acute kidney injury, Severe AKI AKI stage 2 and 3, RRT renal replacement therapy, MAKE major associated kidney events, Shock in ICU catecholamine need during ICU stay, SAPS2 simplified acute physiology score 2